XR 5942Alternative Names: XR-5942
Latest Information Update: 29 Jul 2004
At a glance
- Originator Xenova Group
- Mechanism of Action DNA topoisomerase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 29 Jul 2004 Discontinued - Preclinical for Cancer in United Kingdom (PO)
- 28 Jul 2000 New profile
- 28 Jul 2000 Preclinical development for Cancer in United Kingdom (PO)